Physician profile
Michael J Weaver
NPI 1720427974
$37,847.29
in general payments reported to CMS, 2019-2025
28 companies · $990 in 2025
The $990 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $34K · 2021: $306 · 2022: $671 · 2023: $780 · 2024: $1,115 · 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,741 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,741.08 |
| Education | $143.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $21,400.00 | 2019-2020 | |
| Boston Scientific Corporation | $12,586.00 | 2019-2020 | |
| Abbvie INC. | $1,263.48 | 2021-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $597.09 | 2022-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $414.36 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $362.30 | 2022-2025 | Dupixent |
| Genzyme Corporation | $195.10 | 2023-2025 | |
| Ardelyx, INC. | $150.44 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $115.95 | 2022-2023 | Sutab, Suflave |
| Qol Medical, LLC | $103.71 | 2021-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $95.11 | 2022-2024 | Ocaliva |
| Celltrion USA INC. | $79.47 | 2024-2025 | Vegzelma, Zymfentra |
| Ferring Pharmaceuticals INC. | $64.15 | 2021-2025 | Rebyota |
| Lilly USA, LLC | $54.80 | 2023-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.16 | 2022-2024 | Relistor, Xifaxan |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $48.88 | 2025 | Rezdiffra |
| Mirum Pharmaceuticals, INC. | $37.80 | 2024 | Livmarli |
| Amag Pharmaceuticals, INC. | $32.41 | 2021 | |
| Celgene Corporation | $32.08 | 2023-2024 | Zeposia |
| Orphalan INC | $27.85 | 2025 | Cuvrior |
| Ipsen Biopharmaceuticals, INC | $22.24 | 2024 | Iqirvo |
| Merck Sharp & Dohme LLC | $20.47 | 2021 | |
| Nestle Healthcare Nutrition INC. | $20.01 | 2022 | |
| Redhill Biopharma INC. | $17.38 | 2021 | |
| Gilead Sciences, INC. | $17.17 | 2023 | |
| Phathom Pharmaceuticals, INC. | $15.05 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $12.12 | 2021 | |
| Ambu INC. | $8.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.